We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties. You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies. In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Biotech Stocks Roundup: CMRX Up on JAZZ Bid, MRNA Up on Updates & More
Read MoreHide Full Article
Mergers and acquisitions grabbed the spotlight in the biotech sector this week after Jazz Pharmaceuticals (JAZZ - Free Report) announced an agreement to acquire Chimerix (CMRX - Free Report) . Meanwhile, other pipeline and regulatory updates were in focus.
The Week’s Most Important Biotech Stocks Stories:
CMRX Stock Surges on JAZZ Acquisition Bid
Shares of clinical-stage biotech Chimerix skyrocketed following an acquisition agreement from Jazz Pharmaceuticals for $8.55 per share in cash, aggregating to nearly $935 million.
The offer price reflects an approximately 72% premium based on CMRX’ closing price on Tuesday.
The acquisition will add CMRX’s lead pipeline drug, dordaviprone, to Jazz’s pipeline. This drug is currently under review by the FDA under the accelerated approval pathway as a potential treatment for adult and pediatric patients with recurrent H3 K27M-mutant diffuse glioma. A final decision is expected by Aug. 18, 2025.
Chimerix has another clinical candidate, ONC206, which is being evaluated in early-stage, dose-escalating studies for adult and pediatric patients with advanced central nervous system tumors.
The transaction has been approved by both companies and is expected to be closed in the second quarter of 2025.
The addition of Chimerix’s drug could help Jazz expand its oncology portfolio and further diversify its revenue stream.
MRNA Stock Pops on Updates
Shares of Moderna (MRNA - Free Report) gained after a couple of SEC filings showed that two board members bought shares on the open market. Moderna’s CEO Stephane Bancel and director Paul Sagan acquired common stock worth $6 million.
MRNA also secured a legal victory in a patent dispute against Pfizer and BioNTech. A German court ruled that Pfizer and BioNTech infringed Moderna's COVID-19 vaccine patent. The ruling required both Pfizer and BioNTech to compensate the company, though the final amount will be determined in further proceedings.
Regulatory Update From GSK
GSK plc (GSK - Free Report) announced that the FDA accepted its biologics license application (BLA) for pipeline candidate, depemokimab, in two indications.
The BLA is seeking approval of the candidate as an add-on maintenance treatment of asthma in adult and pediatric patients aged 12 years and older with type 2 inflammation characterized by an eosinophilic phenotype on medium to high-dose inhaled corticosteroids (ICS) plus another asthma controller. GSK is also looking to get the candidate approved as an add-on maintenance treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP).
The regulatory body has set a target action date of Dec. 16, 2025.
The BLA is based on data from positive SWIFT and ANCHOR trials. SWIFT-1 and -2 showed depemokimab reduced exacerbation and hospitalization rates as an add-on therapy for patients with asthma with type 2 inflammation versus placebo. ANCHOR-1 and 2 showed early and sustained reductions in nasal polyp size and nasal obstruction versus placebo.
REGN’s MM Drug Gets Positive CHMP Opinion
Regeneron Pharmaceuticals, Inc. (REGN - Free Report) obtained a positive opinion for its pipeline candidate, linvoseltamab, from the European Medicines Agency’s (“EMA”) Committee for Medicinal Products for Human Use (“CHMP”).
The CHMP recommended conditional marketing authorization of linvoseltamab to treat adults with relapsed and refractory (R/R) multiple myeloma (MM). The recommendation is specific to those who have received at least three prior therapies, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
The positive CHMP opinion is supported by data from the pivotal LINKER-MM1 trial, which evaluated linvoseltamab in adults with R/R MM. A final decision is expected in the coming months.
Last month, the FDA accepted the BLA for linvoseltamab for review and set a target action date of July 10, 2025.
The Nasdaq Biotechnology Index has increased 2.62% in the past five trading sessions and MRNA’s shares increased 4.85%. In the past six months, shares of MRNA have plunged 52.06%. (See the last biotech stock roundup here: Biotech Stock Roundup: BLUE Down on Update, News From GILD, TRDA)
Image Source: Zacks Investment Research
What's Next in Biotech?
Stay tuned for more pipeline updates.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Biotech Stocks Roundup: CMRX Up on JAZZ Bid, MRNA Up on Updates & More
Mergers and acquisitions grabbed the spotlight in the biotech sector this week after Jazz Pharmaceuticals (JAZZ - Free Report) announced an agreement to acquire Chimerix (CMRX - Free Report) . Meanwhile, other pipeline and regulatory updates were in focus.
The Week’s Most Important Biotech Stocks Stories:
CMRX Stock Surges on JAZZ Acquisition Bid
Shares of clinical-stage biotech Chimerix skyrocketed following an acquisition agreement from Jazz Pharmaceuticals for $8.55 per share in cash, aggregating to nearly $935 million.
The offer price reflects an approximately 72% premium based on CMRX’ closing price on Tuesday.
The acquisition will add CMRX’s lead pipeline drug, dordaviprone, to Jazz’s pipeline. This drug is currently under review by the FDA under the accelerated approval pathway as a potential treatment for adult and pediatric patients with recurrent H3 K27M-mutant diffuse glioma. A final decision is expected by Aug. 18, 2025.
Chimerix has another clinical candidate, ONC206, which is being evaluated in early-stage, dose-escalating studies for adult and pediatric patients with advanced central nervous system tumors.
The transaction has been approved by both companies and is expected to be closed in the second quarter of 2025.
The addition of Chimerix’s drug could help Jazz expand its oncology portfolio and further diversify its revenue stream.
MRNA Stock Pops on Updates
Shares of Moderna (MRNA - Free Report) gained after a couple of SEC filings showed that two board members bought shares on the open market. Moderna’s CEO Stephane Bancel and director Paul Sagan acquired common stock worth $6 million.
MRNA also secured a legal victory in a patent dispute against Pfizer and BioNTech. A German court ruled that Pfizer and BioNTech infringed Moderna's COVID-19 vaccine patent. The ruling required both Pfizer and BioNTech to compensate the company, though the final amount will be determined in further proceedings.
Regulatory Update From GSK
GSK plc (GSK - Free Report) announced that the FDA accepted its biologics license application (BLA) for pipeline candidate, depemokimab, in two indications.
The BLA is seeking approval of the candidate as an add-on maintenance treatment of asthma in adult and pediatric patients aged 12 years and older with type 2 inflammation characterized by an eosinophilic phenotype on medium to high-dose inhaled corticosteroids (ICS) plus another asthma controller. GSK is also looking to get the candidate approved as an add-on maintenance treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP).
The regulatory body has set a target action date of Dec. 16, 2025.
The BLA is based on data from positive SWIFT and ANCHOR trials. SWIFT-1 and -2 showed depemokimab reduced exacerbation and hospitalization rates as an add-on therapy for patients with asthma with type 2 inflammation versus placebo. ANCHOR-1 and 2 showed early and sustained reductions in nasal polyp size and nasal obstruction versus placebo.
REGN’s MM Drug Gets Positive CHMP Opinion
Regeneron Pharmaceuticals, Inc. (REGN - Free Report) obtained a positive opinion for its pipeline candidate, linvoseltamab, from the European Medicines Agency’s (“EMA”) Committee for Medicinal Products for Human Use (“CHMP”).
The CHMP recommended conditional marketing authorization of linvoseltamab to treat adults with relapsed and refractory (R/R) multiple myeloma (MM). The recommendation is specific to those who have received at least three prior therapies, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
The positive CHMP opinion is supported by data from the pivotal LINKER-MM1 trial, which evaluated linvoseltamab in adults with R/R MM. A final decision is expected in the coming months.
Last month, the FDA accepted the BLA for linvoseltamab for review and set a target action date of July 10, 2025.
REGN currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Biotech Stocks Performance
The Nasdaq Biotechnology Index has increased 2.62% in the past five trading sessions and MRNA’s shares increased 4.85%. In the past six months, shares of MRNA have plunged 52.06%. (See the last biotech stock roundup here: Biotech Stock Roundup: BLUE Down on Update, News From GILD, TRDA)
Image Source: Zacks Investment Research
What's Next in Biotech?
Stay tuned for more pipeline updates.